Skip to content

The Effects of tDCS on Pain and Metabolite Changes in Patient with Spinal Cord Injury and Neuropathic Pain

The Effects of tDCS on Pain and Metabolite Changes in Patient with Spinal Cord Injury and Neuropathic Pain

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
TCTR
Registry ID
TCTR20170822003
Enrollment
Unknown
Registered
2017-08-22
Start date
2013-11-06
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Previous research has shown that transcranial direct current stimulation (tDCS) can produce pain relief in individuals with neuropathic pain (NP)&#44

Interventions

The study was a pilot study performed over 5 weeks consisting of: (1) a 1&#45
week baseline assessment
(2) 5 consecutively days of 2 mA anodal transcranial direct current stimulation for 20 min
and (3) a 3&#45
week follow up period. Study measures were administered during baseline and during treatment&#44
and then again weekly during the follow&#45
Experimental Device
Treatment group

Sponsors

Khon Kaen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) right handed traumatic spinal cord injury due to an accident, a gunshot, or disease; (2) bilateral pain that was had the same intensity on both sides of the body with an average pain intensity rating before tDCS treatment of 4 or greater, as measured by a 0-10 numerical rating scale (0 = “No pain” to 10 = “Worst pain that you could imagine”); (3) presenting with a pain problem that was refractory to medications, including tricyclic antidepressants, antiepileptic drugs, and/or opioids (i.e., pain that does not respond to at least two of these drugs supplied in adequate doses for 6 months); (4) no evidence of progressive neurological disease or other secondary conditions that could impact pain; and (5) not having used an alternative treatment for pain (herbal remedies and other alternative therapies) in the previous month.

Exclusion criteria

Exclusion criteria: (1) a diagnosis of syringomyelia; (2) current or history of drug abuse or addiction; (3) current psychiatric disorder such as schizophrenia (per medical record), depression (as indicated by a score of 16 or greater on the Beck Depression Inventory(BDI); Wongchai, 2003) or severe anxiety (as indicated by a score of 39 or lower – lower scores indicate greater anxiety – on the Anxiety scale of the Symptom Checklist-90 [SCL-90; Department of Mental Health, 2011a]); (4) significant cognitive deficits (as indicated by a score of 22 or lower on the Thai Mental State Examination [Department of Mental Health, 2011b]); (5) history of loss of consciousness or post-traumatic amnesia at the time of injury; (6) skull defects that would interfere with tDCS treatment; and (7) contraindications for undergoing an MRI scan, i.e., patients who have a heart pacemaker, a metallic foreign body (metal sliver) in their eye, or an aneurysm clip in their brain, severe claustrophobia.

Design outcomes

Primary

MeasureTime frame
Brain metabolytes Pre treatment and Post-treatment day 0, week 1, week 2, week 3 MRS

Secondary

MeasureTime frame
Pain score Pre treatment and Post-treatment day 0, week 1, week 2, week 3 NRS

Countries

Thailand

Contacts

Public ContactParadee Auvichayapat

Khon Kaen University

aparad@kku.ac.th66896222624

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026